Chimeric T-cell receptors: New challenges for targeted immunotherapy in hematologic malignancies

Haematologica

Volumn 92, Issue 3, 2007, Pages 381-388

  Biagi, Ettore ^a,b   Marin, Virna ^a   Attianese, Greta Maria Paola Giordano ^a   Dander, Erica ^a   D'Amico, Giovanna ^a   Biondi, Andrea ^a  

^a SAN GERARDO HOSPITAL   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Chimeric T cell receptor; Hematologic malignancy; Immunotherapy

Indexed keywords

ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CHIMERIC T CELL RECEPTOR; GANCICLOVIR; MONOCLONAL ANTIBODY; RITUXIMAB; T LYMPHOCYTE RECEPTOR; THYMIDINE KINASE; UNCLASSIFIED DRUG; CD30 ANTIGEN; CD33 ANTIGEN; DIFFERENTIATION ANTIGEN; HYBRID PROTEIN; LEUKOCYTE ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ANTIGEN BINDING; CELL SPECIFICITY; CELL SURFACE; CORD BLOOD STEM CELL TRANSPLANTATION; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; NONHUMAN; REVIEW; SUICIDE GENE THERAPY; TUMOR CELL; UMBILICAL CORD BLOOD; ADULT; ANIMAL; BLOOD DISEASE; CHILD; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; FORECASTING; GENETICS; IMMUNOLOGY; METHODOLOGY; NATURAL KILLER CELL; NEOPLASM;

ADULT; ANIMALS; ANTIGENS, CD; ANTIGENS, CD19; ANTIGENS, CD20; ANTIGENS, CD30; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTIGENS, NEOPLASM; CHILD; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; FORECASTING; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES, CYTOTOXIC;

EID: 34247582928     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10873     Document Type: Review

References (64)

1. Bordignon C, Carlo-Stella C, Colombo MP, De Vincentiis A, Lanata L, Lemoli RM, et al. Cell therapy: achievements and perspectives. Haematologica 1999;84:1110-49.
2. Biagi E, Rousseau RF, Yvon E, Vigouroux S, Dotti G, Brenner MK. Cancer vaccines: dream, reality, or nightmare? Clin Exp Med 2002; 2:109-18.
3. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6:383-93.
4. Waldmann TA. Immunotherapy: past, present and future. Nat Med 2003;9:269-77.
5. Campoli M, Ferrone S, Zea AH, Rodriguez PC, Ochoa AC. Mechanisms of tumor evasion. Cancer Treat Res 2005;123:61-88.
6. Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004;22: 1136-51.
7. Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology 2006;117:433-42.
8. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6:295-307.
9. Wang RF. Functional control of regulatory T cells and cancer immunotherapy. Semin Cancer Biol 2006;16: 106-14.
10. Giordano R, Lazzari L, Rebulla P. Clinical grade cell manipulation. Vox Sang 2004;87:65-72.
11. Nienhuis AW, Dunbar CE, Sorrentino BP. Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther 2006;13:1031-49.
12. Pule M, Bollard CM, Heslop HE. Genetically engineered T-cells for adoptive immunotherapy. Curr Opin Mol Ther 2002;4:467-75.
13. Pule M, Finney H, Lawson A. Artificial T-cell receptors. Cytotherapy 2003;5:211-26.
14. Rossig C, Brenner MK. Chimeric T-cell receptors for the targeting of cancer cells. Acta Haematol 2003; 110: 154-9.
15. Rossig C, Brenner MK. Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther 2004;10:5-18.
16. Dotti G, Heslop HE. Current status of genetic modification of T cells for cancer treatment. Cytotherapy 2005; 7:262-72.
17. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virusspecific T lymphocytes. Nat Med 1996;2:551-5.
18. Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-arr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998;92:1549-55.
19. Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss PA, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003;362:1375-7.
20. Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99:3916-22.
21. Riviere I, Sadelain M, Brentjens RJ. Novel strategies for cancer therapy: the potential of genetically modified T lymphocytes. Curr Hematol Rep 2004;3:290-7.
22. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993;90:720-4.
23. Friedmann-Morvinski D, Bendavid A, Waks T, Schindler D, Eshhar Z. Redirected primary T cells harboring a chimeric receptor require co-stimulation for their antigen-specific activation. Blood 2005;105:3087-93.
24. Brentjens RJ. Novel approaches to immunotherapy for B-cell malignancies. Curr Hematol Rep 2005;4:64-72.
25. Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, et al. Eradication or systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003; 9:279-86.
26. Cooper LJ, Topp MS, Serrano LM, Gonzalez S, Chang WC, Naranjo A, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 2003;101:1637-44.
27. Cooper LJ, Al-Kadhimi Z, Serrano LM, Pfeiffer T, Olivares S, Castro A, et al. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by co-transfer of T cells modified to present influenza MP1. Blood 2005;105:1622-31.
28. Serrano LM, Pfeiffer T, Olivares S, Numbenjapon T, Bennitt J, Kim D, et al Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for post-transplantation adoptive immunotherapy. Blood 2006;107:2643-52.
29. Cooper LJ, Ausubel L, Gutierrez M, Stephan S, Shakeley R, Olivares S, et al. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy or lymphoma. Cytotherapy 2006;8:105-17.
30. Roessig C, Scherer SP, Baer A, Vormoor J, Rooney CM, Brenner MK, Juergens H. Targeting CD19 with genetically modified EBV-specific human T lymphocytes. Ann Hematol 2002;81 Suppl 2:S42-3.
31. Rossig C, Bar A, Pscnerer S, Altvater B, Pule M, Rooney CM, et al. Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors. J Immunother 2006;29: 21-31.
32. Pule MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 2005; 12:933-41.
33. Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004; 18:676-84.
34. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005;106:376-83.
35. Marin V, Dander E, Biagi E, Introna M, Fazio G, Biondi A, et al. Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. Exp Hematol 2006; 34:1218-28.
36. Jensen MC, Cooper LJ, Wu AM, Forman SJ, Raubitschek A Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy 2003;5:131-8.
37. + cytotoxic T lymphocytes. Mol Ther 2004;9:577-86.
38. +leukemia cells by a natural killer cell line modified with a chimeric receptor. Leuk Res 2005; 29:301-6.
39. Hombach A, Heuser C, Sircar R, Tillmann T, Diehl V, Pohl C, et al. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen. J Immunother 1999; 22:473-80.
40. +cutaneous lymphoma cells. Gene Ther 2001;8:891-5.
41. + T cells in human immunodeficiency virus-infected subjects. Blood 2000; 96: 785-93.
42. Deeks SG, Wagner B, Anton PA, Mitsuyasu RT, Scadden DT, Huang C, et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther 2002;5:788-97.
43. Mommaas B, van Halteren AG, Pool J, van der Veken L, Wieles B, Heemskerk MH, et al. Adult and cord blood T cells can acquire HA-1 specificity through HA-1 T-cell receptor gene transfer. Haematologica 2005;90:1415-21.
44. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9.
45. Hombach A, Schneider C, Sent D, Koch D, Willemsen RA, et al. An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood T cells to specific lysis of carcinoembryonic antigenpositive tumor cells. Int J Cancer 2000;88:115-20.
46. Finney HM, Lawson AD, Bebbington CR, Weir AN. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 1998;161:2791-7.
47. Fitzer-Attas CJ, Schindler DG, Waks T, Eshhar Z. Harnessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the variable domain receptors: optimal design for T cell activation. J Immunol 1998;160:145-54.
48. Geiger TL, Nguyen P, Leitenberg D, Flavell RA. Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. Blood 2001;98:2364-71.
49. Heemskerk MH, Hagedoorn RS, van der Hoorn MA, van der Veken LT, Hoogeboom M, Kester MG, et al. Efficiency of T cell receptor expression in dual specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood 2007;109:235-43.
50. +-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma. J Virol 2004;78:768-78.
51. Rossig C, Bollard CM, Nuchtern JG, Rooney CM, Brenner MK. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 2002;99:2009-16.
52. Heemskerk MH, Hoogeboom M, Hagedoorn R, Kester MG, Willemze R, Falkenburg JH. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med 2004;199:885-94.
53. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003;348:255-6.
54. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302:415-19.
55. Dave UP, Jenkins NA, Copeland NG. Gene therapy insertional mutagenesis insights. Science 2004; 303: 33.
56. Kohn DB, Sadelain M, Dunbar C, Bodine D, Kiem HP, Candotti F, et al. American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther 2003;8:180-7.
57. Kohn DB, Sadelain M, Glorioso JC. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 2003;3:477-88.
58. Qasim W, Gaspar HB, Thrasher AJ. T cell suicide gene therapy to aid haematopoietic stem cell transplantation. Curr Gene Ther 2005;5:121-32.
59. Li LH, Shivakumar R, Feller S, Allen C, Weiss JM, Dzekunov S, et al. Highly efficient, large volume flow electroporation. Technol Cancer Res Treat 2002;1:341-50.
60. Ellis J. Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum Gene Ther 2005;16:1241-6.
61. Straathof KC, Pule MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005; 105:4247-54.
62. Introna M, Barbui AM, Golay J, Rambaldi A. Innovative cell-based therapies in onco-hematology: what are the clinical facts? Haematologica 2004;89:1253-60.
63. Rudd CE, Schneider H. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat Rev Immunol 2003;3:544-56.
64. Watts TH. TNF/TNFR family members in co-stimulation of T cell responses. Annu Rev Immunol 2005;23:23-68.